AACR20: ovarian cancer mortality could be improved with lipophilic statins

Written by Rachel Jenkins, Future Science Group

Recently presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, a study has demonstrated that lipophilic statins can reduce mortality in ovarian cancer patients. The medication, common prescribed to lower blood cholesterol, was investigated in this study of 10,062 women with ovarian cancer, allowing researchers to evaluate different statin types and their impact of different subtypes of ovarian cancer. Researchers linked data from the Finnish national cancer registry to prescription claims on 10,062 women diagnosed with ovarian cancer between 1995–2015. A total of 2261 patients used statins, of which, 80% used lipophilic statins. The results demonstrated...

To view this content, please register now for access

It's completely free